6 stories mentioning INSPUpdated 7m ago
Every FINWIRES story that references INSP, newest first.
Inspire Medical Systems (INSP) has an average rating of hold and mean price target of $50.85, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
Inspire Medical Systems (INSP) faces risks to estimates and the stock is unlikely to perform without consistent clarity on coding pathways for centers, BofA Securities said in a Friday research note.The company's guidance assumes 2027 revenue will grow but it is difficult to predict a sustainable improvement until there is an official Category 1 code for the Inspire V leadless hypoglossal nerve stimulation system.The brokerage lowered its 2027 EPS estimate to $1 from $1.15 and its revenue forecast to $854 million from $863 million earlier. The EPS estimate for 2028 was trimmed down to $1.28 from $1.35 and the revenue forecast was cut to $907 million from $917 million.The company witnessed a decline in prior authorization submissions in Q1, but sees Q2 as the trough in growth, given early signs of PA volumes stabilizing and improving as centers gain coding experience, according to the note.BofA downgraded the stock to underperform from neutral and cut its price target to $39 per share from $53.Shares of Inspire Medical were down nearly 4% in Friday trading.Price: $43.07, Change: $-1.67, Percent Change: -3.73%
Inspire Medical Systems (INSP) has an average rating of hold and mean price target of $52, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
Inspire Medical Systems (INSP) has limited visibility on near- and medium-term trends after the firm lowered its 2026 revenue guidance due to impact of Inspire V coding headwinds, RBC Capital Markets said in a Monday note.The report said the guidance cut is reflecting accelerated coding and reimbursement challenges to Inspire V, while additional WISeR/GLP-1 headwinds emerge.The headwinds align with intra-quarter RBC Doctor Day checks that highlighted that several factors will likely continue to drive Inspire volumes lower throughout 2026, it said.The report also said the medical technology company, which focuses on obstructive sleep apnea, doesn't expect a new CPT code for Inspire V until Jan. 1, 2028."We remain on the sidelines due to lack of visibility," the note said. RBC kept its Sector Perform rating while lowering its price target to $45 from $56.Price: $45.71, Change: $-9.13, Percent Change: -16.65%
Inspire Medical Systems (INSP) has an average rating of Hold and mean price target of $55, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
Inspire Medical Systems (INSP) has an average rating of Hold and mean price target of $55, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
